BACKGROUND: Accumulation of tau leads to neuroinflammation and neuronal cell death in tauopathies, including Alzheimer's disease. As the disease progresses, there is a decline in brain energy metabolism. However, the role of tau protein in regulating lipid metabolism remains less characterized and poorly understood. METHODS: We used a transgenic rat model for tauopathy to reveal metabolic alterations induced by neurofibrillary pathology. Transgenic rats express a tau fragment truncated at the N- and C-terminals. For phenotypic profiling, we performed targeted metabolomic and lipidomic analysis of brain tissue, CSF, and plasma, based on the LC-MS platform. To monitor disease progression, we employed samples from transgenic and control rats aged 4, 6, 8, 10, 12, and 14 months. To study neuron-glia interplay in lipidome changes induced by pathological tau we used well well-established multicomponent cell model system. Univariate and multivariate statistical approaches were used for data evaluation. RESULTS: We showed that tau has an important role in the deregulation of lipid metabolism. In the lipidomic study, pathological tau was associated with higher production of lipids participating in protein fibrillization, membrane reorganization, and inflammation. Interestingly, significant changes have been found in the early stages of tauopathy before the formation of high-molecular-weight tau aggregates and neurofibrillary pathology. Increased secretion of pathological tau protein in vivo and in vitro induced upregulated production of phospholipids and sphingolipids and accumulation of lipid droplets in microglia. We also found that this process depended on the amount of extracellular tau. During the later stages of tauopathy, we found a connection between the transition of tau into an insoluble fraction and changes in brain metabolism. CONCLUSION: Our results revealed that lipid metabolism is significantly affected during different stages of tau pathology. Thus, our results demonstrate that the dysregulation of lipid composition by pathological tau disrupts the microenvironment, further contributing to the propagation of pathology.
- MeSH
- Alzheimerova nemoc * patologie MeSH
- krysa rodu rattus MeSH
- metabolismus lipidů MeSH
- modely nemocí na zvířatech MeSH
- mozek metabolismus MeSH
- myši transgenní MeSH
- myši MeSH
- neurofibrilární klubka metabolismus MeSH
- potkani transgenní MeSH
- proteiny tau genetika metabolismus MeSH
- tauopatie * patologie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
In Alzheimer's disease (AD), two mutually exclusive amino-terminal-dependent conformations have been reported to occur during the aggregation of Tau protein into neurofibrillary tangles (NFTs). An early conformation of full-length Tau, involving the bending of the amino terminus over the third repeated domain, is recognized by the Alz-50 antibody, followed by a second conformation recognized by Tau-66 antibody that depends on the folding of the proline-rich region over the third repeated domain in a molecule partially truncated at the amino- and carboxyl-termini. α-1-antichymotrypsin (ACT) is an acute phase serum glycoprotein that accumulates abnormally in the brain of AD patients, and since it is considered to promote the in vitro and in vivo aggregation of amyloid-β, we here seek further evidence that ACT may also contribute to the abnormal aggregation of Tau in AD. By analyzing brain samples from a population of AD cases under immunofluorescence and high-resolution confocal microscopy, we demonstrate here the abundant expression of ACT in hippocampal neurons, visualized as a granular diffuse accumulation, frequently reaching the nuclear compartment. In a significant number of these neurons, intracellular NFTs composed of abnormally phosphorylated and truncated Tau at Asp421 were also observed to coexist in separated regions of the cytoplasm. However, we found strong colocalization between ACT and diffuse aggregates of Tau-66-positive granules, which was not observed with Alz-50 antibody. These results suggest that ACT may play a role during the development of Tau conformational changes facilitating its aggregation during the formation of the neurofibrillary pathology in AD.
In Alzheimer's disease, tau protein undergoes post-translational modifications including hyperphosphorylation and truncation, which promotes two major conformational changes associated with progressive N-terminal folding. Along with the development of the disease, tau ubiquitination was previously shown to emerge in the early and intermediate stages of the disease, which is closely associated with early tau truncation at aspartic acid 421, but not with a subsequently truncated tau molecule at glutamic acid 391. In the same group of cases, using multiple immunolabeling and confocal microscopy, a possible relationship between the ubiquitin-targeting of tau and the progression of conformational changes adopted by the N-terminus of this molecule was further studied. A comparable number of neurofibrillary tangles was found displaying ubiquitin, an early conformation recognized by the Alz-50 antibody, and a phosphorylation. However, a more reduced number of neurofibrillary tangles were immunoreactive to Tau-66 antibody, a late tau conformational change marker. When double-labeling profiles of neurofibrillary tangles were assessed, ubiquitination was clearly demonstrated in tau molecules undergoing early N-terminal folding, but was barely observed in late conformational changes of the N-terminus adopted by tau. The same pattern of colocalization was visualized in neuritic pathology. Overall, these results indicate that a more intact conformation of the N-terminus of tau may facilitate tau ubiquitination, but this modification may not occur in a late truncated and more compressed folding of the N-terminus of the tau molecule.
- MeSH
- Alzheimerova nemoc metabolismus patologie MeSH
- konformace proteinů MeSH
- lidé středního věku MeSH
- lidé MeSH
- mozek metabolismus patologie MeSH
- neurofibrilární klubka chemie patologie MeSH
- proteiny tau chemie metabolismus MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ubikvitinace fyziologie MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Rozsáhlá literatura posledních 40 let obviňuje mozkový amyloid jako jeden z kauzálních faktorů stařecké demence. Amyloid je tak tradován spolu s fibrilárními intracelulárními inkluzemi τ-proteinu jako původce specifické Alzheimerovy nemoci. Poté, co jsme byli dlouhá desetiletí závislí na amyloidní detekci v pitevních vzorcích, dosahuje dnes použití radioaktivních ligandů cestou pozitronové emisní tomografie (PET) vysoce instruktivních nálezů in vivo. Poznání souvislostí mezi duševním výkonem a intenzitou amyloidních depozit dostalo tedy nový rozměr. Poskytujeme přehled metod a jejich závěrů, které přinášejí nové světlo do mechanizmů stárnoucího mozku: histologické vlastnosti amyloidu, techniky a výtěžnost jeho detekce v PET, vztah denzity amyloidu k denzitě neurofibrilárních klubíček, vztah k intenzitě tkáňového metabolizmu a atrofii, dynamiku výskytu vzhledem k věku probanda a korelační studie mezi amyloidem a duševním výkonem. Podaný výklad zpochybňuje kauzální roli amyloidu v duševní deterioraci seniorů, a tím i jeden z pilířů tzv. Alzheimerovy nemoci.
Extensive literature from the past 40 years accuses brain amyloid as one of the causal factors of senile dementia. Amyloid is considered, together with intracellular inclusions of τ-protein, as the originator for a specific Alzheimer‘s disease. After being dependent for many decades on amyloid detection only in autopsy specimens, the application of radioactive ligands using positron emission tomography (PET) currently achieves highly informative in vivo findings. The recognition of relations between mental acuity and the intensity of amyloid deposits has thus obtained a new dimension. We are providing a review of methods and their conclusions which shed light onto the mechanisms of brain ageing: histological properties of amyloid, techniques and the yield of its detection in PET, relation of amyloid density to that of neurofibrillary tangles, its relation to tissue metabolism and atrophy, dynamics of amyloid presence according to age and correlative studies between amyloid and mental effectivity. The given interpretation puts doubt on the causal role of amyloid in the psychic deterioration of seniors and thus also on one of the pillars of the so-called Alzheimer‘s disease.
- MeSH
- Alzheimerova nemoc * diagnostické zobrazování metabolismus patologie MeSH
- amyloidní beta-protein * MeSH
- amyloidní plaky diagnostické zobrazování metabolismus MeSH
- fluorodeoxyglukosa F18 metabolismus MeSH
- kognitivní poruchy MeSH
- lidé MeSH
- mozek diagnostické zobrazování metabolismus patologie MeSH
- neurofibrilární klubka * MeSH
- pozitronová emisní tomografie MeSH
- stárnutí MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
Rozsáhlá literatura posledních 40 let obviňuje mozkový amyloid jako jeden z kauzálních faktorů stařecké demence. Amyloid je tak tradován spolu s fibrilárními intracelulárními inkluzemi τ-proteinu jako původce specifické Alzheimerovy nemoci. Poté, co jsme byli dlouhá desetiletí závislí na amyloidní detekci v pitevních vzorcích, dosahuje dnes použití radioaktivních ligandů cestou pozitronové emisní tomografie (PET) vysoce instruktivních nálezů in vivo. Poznání souvislostí mezi duševním výkonem a intenzitou amyloidních depozit dostalo tedy nový rozměr. Poskytujeme přehled metod a jejich závěrů, které přinášejí nové světlo do mechanizmů stárnoucího mozku: histologické vlastnosti amyloidu, techniky a výtěžnost jeho detekce v PET, vztah denzity amyloidu k denzitě neurofibrilárních klubíček, vztah k intenzitě tkáňového metabolizmu a atrofii, dynamiku výskytu vzhledem k věku probanda a korelační studie mezi amyloidem a duševním výkonem. Podaný výklad zpochybňuje kauzální roli amyloidu v duševní deterioraci seniorů, a tím i jeden z pilířů tzv. Alzheimerovy nemoci.
Extensive literature from the past 40 years accuses brain amyloid as one of the causal factors of senile dementia. Amyloid is considered, together with intracellular inclusions of τ-protein, as the originator for a specific Alzheimer‘s disease. After being dependent for many decades on amyloid detection only in autopsy specimens, the application of radioactive ligands using positron emission tomography (PET) currently achieves highly informative in vivo findings. The recognition of relations between mental acuity and the intensity of amyloid deposits has thus obtained a new dimension. We are providing a review of methods and their conclusions which shed light onto the mechanisms of brain ageing: histological properties of amyloid, techniques and the yield of its detection in PET, relation of amyloid density to that of neurofibrillary tangles, its relation to tissue metabolism and atrophy, dynamics of amyloid presence according to age and correlative studies between amyloid and mental efectivity. The given interpretation puts doubt on the causal role of amyloid in the psychic deterioration of seniors and thus also on one of the pillars of the so-called Alzheimer‘s disease.
- MeSH
- Alzheimerova nemoc etiologie patologie MeSH
- amyloid * fyziologie toxicita MeSH
- amyloidní plaky dějiny patologie MeSH
- demence * etiologie patologie MeSH
- klinické zkoušky jako téma MeSH
- lidé MeSH
- mozek diagnostické zobrazování metabolismus patologie MeSH
- neurofibrilární klubka patologie MeSH
- pozitronová emisní tomografie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
We report a 44-year-old woman, with a family history of early-onset dementia, presenting with primary progressive aphasia. This clinically variable syndrome has multiple underlying pathologies, and correlations between clinical manifestations and postmortem neuropathologic findings are controversial. Our patient suffered worsening language impairment with major word-finding difficulties but preserved comprehension. She also developed episodic memory impairment. Her condition progressed to dementia with behavioral changes. Magnetic resonance imaging showed early left perisylvian and bitemporal atrophy. The patient died shortly afterward from colon cancer. Neuropathologic examination revealed advanced early-onset Alzheimer and Lewy body disease, plus a clinically nonrelevant metastasis of her colon cancer in her left parietal lobe. Genetic examination revealed a p.Glu184Asp mutation in the presenilin1 gene. Our findings confirm the importance of a thorough appreciation for the clinical and neuropathologic correlations in patients with atypical neurodegenerative dementias.
- MeSH
- Alzheimerova nemoc komplikace diagnóza genetika patologie MeSH
- demence s Lewyho tělísky komplikace diagnóza genetika patologie MeSH
- dospělí MeSH
- fatální výsledek MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozek patologie MeSH
- neurity patologie MeSH
- neurofibrilární klubka patologie MeSH
- neuropsychologické testy MeSH
- presenilin-1 genetika MeSH
- primární progresivní afázie diagnóza etiologie patologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- kazuistiky MeSH
Alzheimer's disease (AD) is the most frequent cause of dementia. Misfolded protein pathological hallmarks of AD are brain deposits of amyloid-β (Aβ) plaques and phosphorylated tau neurofibrillary tangles. However, doubts about the role of Aβ in AD pathology have been raised as Aβ is a common component of extracellular brain deposits found, also by in vivo imaging, in non-demented aged individuals. It has been suggested that some individuals are more prone to Aβ neurotoxicity and hence more likely to develop AD when aging brains start accumulating Aβ plaques. Here, we applied genome-wide transcriptomic profiling of lymphoblastoid cells lines (LCLs) from healthy individuals and AD patients for identifying genes that predict sensitivity to Aβ. Real-time PCR validation identified 3.78-fold lower expression of RGS2 (regulator of G-protein signaling 2; P=0.0085) in LCLs from healthy individuals exhibiting high vs low Aβ sensitivity. Furthermore, RGS2 showed 3.3-fold lower expression (P=0.0008) in AD LCLs compared with controls. Notably, RGS2 expression in AD LCLs correlated with the patients' cognitive function. Lower RGS2 expression levels were also discovered in published expression data sets from postmortem AD brain tissues as well as in mild cognitive impairment and AD blood samples compared with controls. In conclusion, Aβ sensitivity phenotyping followed by transcriptomic profiling and published patient data mining identified reduced peripheral and brain expression levels of RGS2, a key regulator of G-protein-coupled receptor signaling and neuronal plasticity. RGS2 is suggested as a novel AD biomarker (alongside other genes) toward early AD detection and future disease modifying therapeutics.
- MeSH
- Alzheimerova nemoc diagnóza genetika patologie MeSH
- amyloidní beta-protein genetika MeSH
- amyloidní plaky genetika patologie MeSH
- buněčné linie MeSH
- časná diagnóza MeSH
- celogenomová asociační studie * MeSH
- data mining * MeSH
- exprese genu genetika MeSH
- fenotyp MeSH
- genetické asociační studie MeSH
- genetické markery genetika MeSH
- lidé MeSH
- mozek patologie MeSH
- neurofibrilární klubka genetika patologie MeSH
- proteiny RGS genetika MeSH
- senioři MeSH
- stanovení celkové genové exprese * MeSH
- výpočetní biologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Alzheimer's disease (AD) involves the propagation of filaments of tau protein throughout the cerebral cortex. Imaging tau filaments and oligomers in human brain at high resolution would help contribute insight into the mechanism and progression of tauopathic diseases. STED microscopy is a nano-scale imaging technique and we aimed to test the abilities of this method for resolving tau structures within human brain. Using autopsied 50μm AD brain sections, we demonstrate that STED microscopy can resolve immunolabelled tau filaments at 77nm resolution. Ribbon-like tau filaments imaged by STED appeared smooth along their axis with limited axial undulations. STED also resolved 70-80nm wide tau puncta. Of the fluorophores tested, STAR635p was optimal for STED imaging in this tissue. This was in part due to brain tissue autofluorescence within the lower wavelength ranges (488-590nm). Further, the stability and minimal photobleaching of STAR635p allowed STED z-stacks of neurons packed with tau filaments (neurofibrillary tangles) to be collated. There was no loss of x-y image resolution of individual tau filaments through the 20μm z-stack. This demonstrates that STED can contribute to nano-scale analysis and characterisation of pathologies within banked human autopsied brain tissue. Resolving tau structures at this level of resolution provides promising avenues for understanding mechanisms of pathology propagation in the different tauopathies as well as illuminating what contributes to disease heterogeneity.
- MeSH
- Alzheimerova nemoc diagnostické zobrazování patologie MeSH
- barvení a značení MeSH
- lidé MeSH
- neurofibrilární klubka patologie ultrastruktura MeSH
- optické zobrazování MeSH
- proteiny tau chemie ultrastruktura MeSH
- šedá hmota diagnostické zobrazování patologie MeSH
- zobrazování trojrozměrné MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Alzheimerova choroba (AD) je jedním z nejzávažnějších onemocnění moderní doby. Vzrůstající průměrný věk společně s vysokou prevalencí a incidencí AD v seniorské populaci, společně s vysokými náklady na péči o pacienty s AD z ní činí jednu z finančně nejnáročnějších diagnóz vůbec. Vakcinace je dlouhodobě označována za nákladově nejefektivnější formu terapeutické intervence, proto není divu, že do imunoterapeutických přístupů k terapii AD jsou vkládány veliké naděje. V tomto přehledovém článku bychom rádi shrnuli dosavadní imunologické přístupy v terapii AD a prezentovali současné trendy výzkumu, které by v dohledné době mohly přinést posun v terapii nebo prevenci AD.
Alzheimer's disease (AD) is one of the plagues of modern era. Increasing mean age of a population in combination with the overall high prevalence and incidence of AD in elderly population and very high both direct and indirect health care costs of the disease, makes AD one of the most expensive diagnosis in the developed countries. Vaccination is one of the best cost effective approaches of the therapeutic interventions. Progresses in immunotherapeutic approaches in AD therapy are watched with great anticipations both by healthcare professionals and general population. In this review we would like to summarize up-to date immunotherapeutic approaches in clinical development and to present current research trends that could lead to the breakthrough in AD therapy or prevention.
- MeSH
- aktivní imunoterapie metody MeSH
- Alzheimerova nemoc * etiologie farmakoterapie imunologie prevence a kontrola MeSH
- amyloidní beta-protein imunologie metabolismus MeSH
- amyloidní plaky MeSH
- histokompatibilita - antigeny třídy I MeSH
- imunoterapie * metody MeSH
- klinické zkoušky jako téma MeSH
- lidé MeSH
- monoklonální protilátky terapeutické užití MeSH
- neurofibrilární klubka MeSH
- pasivní imunizace MeSH
- proteiny tau MeSH
- protilátky terapeutické užití MeSH
- receptory Fc MeSH
- senioři MeSH
- stárnutí MeSH
- vakcíny proti Alzheimerově nemoci * terapeutické užití MeSH
- Check Tag
- lidé MeSH
- senioři MeSH
- Publikační typ
- práce podpořená grantem MeSH
- přehledy MeSH
- tabulky MeSH
Dementia with Lewy bodies (DLB) is characterized by preserved whole brain and medial temporal lobe volumes compared with Alzheimer's disease dementia (AD) on magnetic resonance imaging. However, frequently coexistent AD-type pathology may influence the pattern of regional brain atrophy rates in DLB patients. We investigated the pattern and magnitude of the atrophy rates from 2 serial MRIs in autopsy-confirmed DLB patients (n = 20) and mixed DLB/AD patients (n = 22), compared with AD (n = 30) and elderly nondemented control subjects (n = 15), followed antemortem. DLB patients without significant AD-type pathology were characterized by lower global and regional rates of atrophy, similar to control subjects. The mixed DLB/AD patients displayed greater atrophy rates in the whole brain, temporoparietal cortices, hippocampus and amygdala, and ventricle expansion, similar to AD patients. In the DLB and DLB/AD patients, the atrophy rates correlated with Braak neurofibrillary tangle stage, cognitive decline, and progression of motor symptoms. Global and regional atrophy rates are associated with AD-type pathology in DLB, and these rates can be used as biomarkers of AD progression in patients with LB pathology.
- MeSH
- Alzheimerova nemoc diagnóza patologie MeSH
- amygdala patologie MeSH
- atrofie MeSH
- biologické markery MeSH
- demence s Lewyho tělísky patologie psychologie MeSH
- hipokampus patologie MeSH
- kognice MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- mozek patologie MeSH
- neurofibrilární klubka patologie MeSH
- pitva MeSH
- progrese nemoci MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- spánkový lalok patologie MeSH
- temenní lalok patologie MeSH
- velikost orgánu MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH